European Journal of Dermatology
MENUPsoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab Volume 27, numéro 5, September-October 2017
Illustrations
2 Immunogenetics laboratory,
Instituto Ciências Biomédicas Abel Salazar,
University of Porto,
Portugal
Instituto Ciências Biomédicas Abel Salazar,
University of Porto,
Portugal
- DOI : 10.1684/ejd.2017.3071
- Page(s) : 528-30
- Année de parution : 2017
Psoriasis is a chronic inflammatory disease which is influenced by multiple genetic factors. Current knowledge supports that the same genetic features may influence clinical responsiveness to different therapies [1]. HLACw*0602 polymorphism is the main susceptibility gene in psoriasis and its expression is generally linked to an early onset, longer duration, and severity of the disease [2]. Other genetic risk factors have been identified, namely the IL-23R and IL-12β polymorphisms that are involved [...]